BCL2 and lung carcinoma: Similarly, H460 lung cancer cells with high endogenous Bcl-2 expression also showed BH3 domain exposure following treatment with BFC1108 (Fig. 4D) and exhibited responsiveness to BFC1108 (Fig. 2E).